ReviewBiochemistry and biophysics reports2026
Enhancement of prime editing by recruiting engineered or evolved components and implementing novel strategies.
Review in Biochemistry and biophysics reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prime editing has recently gained attention for its promising potential in treating genetic disorders caused by different types of mutations. This method, based on Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR), has led to the development of new strategies that offer improved editing efficiency. Additionally, the components of prime editing-namely, the prime editor (PE) and the prime editing guide RNA (PegRNA)-have been enhanced through rational design and direct evolution of structural modifications. These improvements have resulted in better performance and new capabilities, driven by novel mutations or components. In this review, we compare various studies that report enhanced versions of PE or PegRNA, which achieve more efficient results. These advancements hold the potential to accelerate and simplify the development of gene therapies for a range of genetic disorders.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.